NCT02819271View on ClinicalTrials.gov

A First-in-Human Study of the Safety of Single Continuous Intravenous (IV) Infusions of CXL-1427 for up to 48 Hours in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 28, 2014

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Heart Failure
Interventions
DRUG

CXL-1427 Ascending Dose

OTHER

Placebo

DRUG

CXL-1427 Descending Dose

Sponsors
All Listed Sponsors
collaborator

Cardioxyl Pharmaceuticals, Inc

INDUSTRY

lead

Bristol-Myers Squibb

INDUSTRY